Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

Table 1 Estimated distribution goodness of fit values of progression-free survival and overall survival

Distribution	Weibull^a	Exponential^b	Gompertz^a	Loglogistic^c	Lognormal^d
PFS cabozantinib
SSR	0,012	0,026	0,016	0,021	0,015
AIC	−188	−170	− 180	− 173	− 181
BIC	− 185	− 168	−178	−171	− 179
OS cabozantinib
SSR	0,010	0,032	0,016	0,019	0,014
AIC	− 337	− 292	− 317	−312	− 322
BIC	− 334	− 290	− 314	− 308	− 319
PFS BSC
SSR	0,070	0,080	0,080	0,035	0,039
AIC	− 143	− 142	− 140	− 160	−158
BIC	− 140	−140	− 137	− 158	− 155
OS BSC
SSR	0,121	0,161	0,154	0,021	0,014
AIC	− 208	− 199	−199	− 273	− 287
BIC	−205	−197	− 196	− 270	− 283

PFS progression-free survival, OS overall survival, BSC best supportive care, SSR sum of squared residuals, AIC Akaike information criterion, BIC Bayesian information criterion. ^a Monotonically increasing. ^b Constant hazard. ^c Increasing followed by a gradually decreasing hazard. ^d Hazard increases to a maximum and then decreases to 0 as time tends to infinity

ISSN: 1471-230X